Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis

Autor: Bonello, F., Pulini, S., Ballanti, S., Gentile, M., Spada, S., Annibali, O., Omede, P., Ronconi, S., Cangialosi, C., Podda, L., Palmas, A., Malfitano, A., Rivoli, G., Belotti, A., Ciambelli, F., Vincelli, I. D., Cafro, A. M., Innao, V., Palumbo, A., Sonneveld, P., Spencer, A., Hajek, R., Boccadoro, M., Gay, F.

Publikováno v: Cancers, Vol 11, Iss 11, p 1735 (2019)
Cancers
Cancers, 11(11):1735. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 11
Issue 11

We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly diagnosed transplant-eligible and -ineligible myeloma patients. Primary endpoints were prog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdcb616a3a39f42ce9199aa113c277a4
https://doi.org/10.3390/cancers11111735

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL.

Autor: Larocca, A., D'Agostino, M., Giuliani, N., Antonioli, E., Zambello, R., Ronconi, S., Vincelli, I. D., Ciceri, F., Falcone, A. P., Michieli, M., Cattel, F., Capra, A., Grasso, M., Cafro, A. M., Bonello, F., Floris, R., Offidani, M., Sciorsi, E., Pietrantuono, G., Curci, P.

Publikováno v: HemaSphere; May2023 Supplement S2, Vol. 7, p12-13, 2p

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

Autor: Morabito, F, Gentile, M, Mazzone, C, Rossi, D, Di Raimondo, F, Bringhen, S, Ria, R, Offidani, M, Patriarca, F, Nozzoli, C, Petrucci, Mt, Benevolo, G, Vincelli, I, Guglielmelli, T, Grasso, M, Marasca, R, Baldini, L, Montefusco, V, Musto, P, Cascavilla, N, Majolino, I, Musolino, Caterina, Cavo, M, Boccadoro, M, Palumbo, A, Musolino, C.

We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f660a0551189313fa2a57fefff3ed0
http://hdl.handle.net/11570/2217021

Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study

Autor: Gentile, M, Cutrona, G, Mosca, L, Matis, S, Fabris, S, Lionetti, M, Ilariucci, F, Zupo, S, Musolino, C, Levato, L, Molica, S, DI RAIMONDO, Francesco, Vincelli, I, Di Rienzo, N, Pesce, Ea, Angrilli, F, Federico, M, Neri, A, Ferrarini, M, Morabito, F.

A risk score based on three biological features (CD38, ZAP-70, and IGHV mutational status) was previously developed to predict progression-free survival (PFS) in untreated Binet A CLL patients. Here we perform a score validation analysis in a prospec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::424868c7e41b0ca72e23753985e066d3
http://hdl.handle.net/11570/3014777